2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer

Gynecol Oncol. 2001 Nov;83(2):310-5. doi: 10.1006/gyno.2001.6386.

Abstract

Objective: The aim of the study was to investigate the role of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) in the diagnosis of recurrent ovarian cancer.

Methods: One hundred six FDG PET scans performed in 54 patients in the follow-up after cytoreductive surgery and chemotherapy of ovarian cancer were reevaluated. Fifty-eight scans were performed in patients with suspected recurrence and 48 scans in patients who were clinically disease free. Thirty-seven PET scans were validated by histology and 66 studies by a median follow-up of 22 months in disease-free patients or 12 months in patients with recurrent disease. Three scans were validated by concordant positive findings of tumor marker CA125, computed tomography, and FDG PET.

Results: FDG PET correctly identified recurrent disease in 73/88 cases. PET ruled out recurrent disease in 15/18 cases. The sensitivity and specificity for PET were 83 and 83%, respectively. In patients with suspected disease, sensitivity was 94% compared to 65% in patients judged clinically disease free. The sensitivity of PET was 96% if suspicion of recurrence was based on a rise of CA125 alone. PET preceded the conventional diagnosis by a median of 6 months in patients judged clinically free of disease. The median relapse-free interval after a negative PET scan was 20 months.

Conclusion: FDG PET provides the chance to detect recurrent ovarian cancer at an earlier stage during follow-up. Patients with a negative PET scan have a longer relapse-free interval than patients with a positive PET scan.

Publication types

  • Clinical Trial

MeSH terms

  • CA-125 Antigen / metabolism
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Iodine Radioisotopes*
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Ovarian Neoplasms / diagnostic imaging*
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / pathology
  • Radiopharmaceuticals*
  • Sensitivity and Specificity
  • Tomography, Emission-Computed

Substances

  • CA-125 Antigen
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18